company background image
HOLX

HologicNasdaqGS:HOLX Stock Report

Last Price

US$70.63

Market Cap

US$17.7b

7D

1.5%

1Y

-6.7%

Updated

21 Jan, 2022

Data

Company Financials +
HOLX fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance6/6
Financial Health4/6
Dividends0/6

HOLX Stock Overview

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally.

Hologic Competitors

Medtronic

NYSE:MDT

US$142.0b

Intuitive Surgical

NasdaqGS:ISRG

US$96.3b

Becton Dickinson

NYSE:BDX

US$75.4b

Edwards Lifesciences

NYSE:EW

US$70.3b

Price History & Performance

Summary of all time highs, changes and price drops for Hologic
Historical stock prices
Current Share PriceUS$70.63
52 Week HighUS$85.00
52 Week LowUS$60.10
Beta1.11
1 Month Change-8.53%
3 Month Change-4.05%
1 Year Change-6.70%
3 Year Change57.55%
5 Year Change74.05%
Change since IPO2,854.46%

Recent News & Updates

Jan 02
Is Hologic (NASDAQ:HOLX) A Risky Investment?

Is Hologic (NASDAQ:HOLX) A Risky Investment?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Shareholder Returns

HOLXUS Medical EquipmentUS Market
7D1.5%-4.5%-6.1%
1Y-6.7%-1.4%4.2%

Return vs Industry: HOLX underperformed the US Medical Equipment industry which returned -0.9% over the past year.

Return vs Market: HOLX underperformed the US Market which returned 6.6% over the past year.

Price Volatility

Is HOLX's price volatile compared to industry and market?
HOLX volatility
HOLX Average Weekly Movement3.9%
Medical Equipment Industry Average Movement8.2%
Market Average Movement6.7%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market2.4%

Stable Share Price: HOLX is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: HOLX's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19856,705Steve MacMillanhttps://www.hologic.com

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus.

Hologic Fundamentals Summary

How do Hologic's earnings and revenue compare to its market cap?
HOLX fundamental statistics
Market CapUS$17.75b
Earnings (TTM)US$1.87b
Revenue (TTM)US$5.63b

9.5x

P/E Ratio

3.2x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
HOLX income statement (TTM)
RevenueUS$5.63b
Cost of RevenueUS$1.56b
Gross ProfitUS$4.07b
ExpensesUS$2.20b
EarningsUS$1.87b

Last Reported Earnings

Sep 25, 2021

Next Earnings Date

Feb 02, 2022

Earnings per share (EPS)7.45
Gross Margin72.35%
Net Profit Margin33.23%
Debt/Equity Ratio71.9%

How did HOLX perform over the long term?

See historical performance and comparison

Valuation

Is Hologic undervalued compared to its fair value and its price relative to the market?

29.9%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: HOLX ($70.63) is trading below our estimate of fair value ($100.75)

Significantly Below Fair Value: HOLX is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: HOLX is good value based on its PE Ratio (9.5x) compared to the US Medical Equipment industry average (46.2x).

PE vs Market: HOLX is good value based on its PE Ratio (9.5x) compared to the US market (16.7x).


Price to Earnings Growth Ratio

PEG Ratio: HOLX's earnings are forecast to decline next year, so we can't calculate its PEG ratio.


Price to Book Ratio

PB vs Industry: HOLX is overvalued based on its PB Ratio (4.2x) compared to the US Medical Equipment industry average (3.4x).


Future Growth

How is Hologic forecast to perform in the next 1 to 3 years based on estimates from 13 analysts?

-44.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: HOLX's earnings are forecast to decline over the next 3 years (-44.5% per year).

Earnings vs Market: HOLX's earnings are forecast to decline over the next 3 years (-44.5% per year).

High Growth Earnings: HOLX's earnings are forecast to decline over the next 3 years.

Revenue vs Market: HOLX's revenue is expected to decline over the next 3 years (-6.4% per year).

High Growth Revenue: HOLX's revenue is forecast to decline over the next 3 years (-6.4% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: HOLX's Return on Equity is forecast to be low in 3 years time (17.8%).


Past Performance

How has Hologic performed over the past 5 years?

35.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: HOLX has high quality earnings.

Growing Profit Margin: HOLX's current net profit margins (33.2%) are higher than last year (29.4%).


Past Earnings Growth Analysis

Earnings Trend: HOLX's earnings have grown significantly by 35.2% per year over the past 5 years.

Accelerating Growth: HOLX's earnings growth over the past year (68.8%) exceeds its 5-year average (35.2% per year).

Earnings vs Industry: HOLX earnings growth over the past year (68.8%) exceeded the Medical Equipment industry 51.2%.


Return on Equity

High ROE: HOLX's Return on Equity (44.3%) is considered outstanding.


Financial Health

How is Hologic's financial position?


Financial Position Analysis

Short Term Liabilities: HOLX's short term assets ($3.2B) exceed its short term liabilities ($1.3B).

Long Term Liabilities: HOLX's short term assets ($3.2B) do not cover its long term liabilities ($3.4B).


Debt to Equity History and Analysis

Debt Level: HOLX's net debt to equity ratio (44.1%) is considered high.

Reducing Debt: HOLX's debt to equity ratio has reduced from 156% to 71.9% over the past 5 years.

Debt Coverage: HOLX's debt is well covered by operating cash flow (76.8%).

Interest Coverage: HOLX's interest payments on its debt are well covered by EBIT (27x coverage).


Balance Sheet


Dividend

What is Hologic current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate HOLX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate HOLX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if HOLX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if HOLX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of HOLX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.2yrs

Average management tenure


CEO

Steve MacMillan (57 yo)

8.08yrs

Tenure

US$14,748,400

Compensation

Mr. Stephen P. MacMillan, also known as Steve, has been the Chairman of the Board at Hologic Inc. since June 17, 2015 and its Chief Executive Officer and President since December 9, 2013. Mr. MacMillan ser...


CEO Compensation Analysis

Compensation vs Market: Steve's total compensation ($USD14.75M) is about average for companies of similar size in the US market ($USD11.42M).

Compensation vs Earnings: Steve's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: HOLX's management team is considered experienced (4.2 years average tenure).


Board Members

Experienced Board: HOLX's board of directors are considered experienced (8.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: HOLX insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Hologic, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Hologic, Inc.
  • Ticker: HOLX
  • Exchange: NasdaqGS
  • Founded: 1985
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Implied Market Cap: US$17.750b
  • Shares outstanding: 251.30m
  • Website: https://www.hologic.com

Number of Employees


Location

  • Hologic, Inc.
  • 250 Campus Drive
  • Marlborough
  • Massachusetts
  • 1752
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/21 23:34
End of Day Share Price2022/01/21 00:00
Earnings2021/09/25
Annual Earnings2021/09/25


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.